Navigation Links
Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
Date:2/15/2008

n

Picoplatin is an intravenous chemotherapeutic agent that has an improved safety profile compared to existing platinum-based chemotherapeutics. It was designed to overcome platinum resistance associated with the treatment of solid tumors. Picoplatin has been evaluated in more than 800 patients and has demonstrated activity in multiple indications with no evidence of significant kidney, nerve toxicity or hearing loss, toxicities commonly observed with other platinum chemotherapy drugs.

In addition to the Phase 2 clinical trial in patients with mHRPC, Poniard is evaluating intravenous picoplatin in an ongoing pivotal Phase 3 trial, known as SPEAR (Study of Picoplatin Efficacy After Relapse), in small cell lung cancer. This registrational trial is being conducted under a Special Protocol Assessment from the U.S. Food and Drug Administration and is evaluating overall survival as the primary endpoint. The Company also is evaluating intravenous picoplatin in an ongoing Phase 2 clinical trial for the treatment of colorectal cancer. Oral picoplatin is being evaluated in a Phase 1 clinical trial in solid tumors.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum therapy with an improved safety profile. Picoplatin is designed to overcome and prevent platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal and hormone-refractory prostate cancer, as well as a clinical trial of oral picoplatin in solid tumors. Picoplatin has not been approved by regulatory authority for use in h
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
2. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
3. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
4. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
5. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
6. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
7. Indevus Pharmaceuticals Provides Update on PRO 2000 Program
8. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
9. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
10. Tigris Pharmaceuticals Initiates Phase I Study of AFP-464 in Patients with Solid Tumors
11. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... EVERETT, Wash. , April 28, 2015  Unfors ... released a new radiation Survey sensor aimed at expanding ... The RaySafe X2 Survey sensor is the easiest and ... energy range. It is the latest addition to the ... the ability to perform leakage and scatter measurements in ...
(Date:4/28/2015)... -- Shares of Celladon Corp. (NASDAQ: CLDN ) lost ... of poor drug trial results of the phase 2B CUPID2 ... The selloff may be warranted or it may be ... prices. An analyst report update on CLDN ... review, analyst summary, valuation, and recommendation can be viewed ...
(Date:4/27/2015)... MARIETTA, Ga., April 27, 2015  MiMedx Group, ... medicine company utilizing human amniotic tissue and patent-protected ... therapies for the Wound Care, Surgical, Orthopedic, Spine, ... announced today its record results for the first ... also announced today the decision of its Board ...
Breaking Medicine Technology:Unfors RaySafe, a Fluke Biomedical company, unveils a new Survey sensor for the RaySafe X2 2Examining what's Left after MYDICAR Drug Trial Ends In Failure; Celladon Corp. Analyst Report Issued by BrokerBank Securities, Inc. 2MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 2MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 3MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 4MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 5MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 6MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 7MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 8MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 9MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 10MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 11MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 12MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 13MiMedx Announces Record Results for First Quarter of 2015 and raises full-year guidance 14
... Ga., Jan. 16, 2012  Molnlycke Health Care US, LLC ... Randy Schwartz, who was the Vice President of Marketing ... been appointed to the position of Global Marketing Director, ... With over 150 years of experience in developing ...
...  Neogen Corporation (NASDAQ: NEOG ) has developed ... mycotoxin zearalenone in grain samples. Zearalenone-contaminated animal feed or ... if eaten by livestock. Neogen,s new Reveal® ... of simple, quick, and fully quantitative tests for mycotoxins ...
Cached Medicine Technology:Molnlycke Health Care U.S. Announces Senior Management Change 2Neogen Develops Simple, Precise Test for Mold Toxin Zearalenone 2
(Date:4/28/2015)... MO (PRWEB) April 28, 2015 The ... 2015 from 5:00 to 8:00 pm at the Sheraton Colonial ... than 50 hospitals, clinics and groups with career opportunities will ... represented. Attendees will enjoy free hors d’oeuvres and raffle prize ... PracticeMatch says “Boston is an ideal location to hold ...
(Date:4/28/2015)... (PRWEB) April 28, 2015 The west ... are among the top areas that healthcare professionals searched ... aureusmedical.com, during the month of March 2015. Data ... in travel nurse jobs , physical therapy ... within nursing and allied health fields. , ...
(Date:4/28/2015)... Foot and Ankle Specialists of the ... ( Annapolis and Clarksville Divisions ) was recently ... Maryland Podiatric Medical Association meeting on April 15, 2015. ... 1992 with a Bachelor of Arts in Life Sciences. ... soccer, track and cross-country. He then attended the New ...
(Date:4/27/2015)... VA (PRWEB) April 28, 2015 Medical ... **Presented by FDAnews and Ombu Enterprises**, June 16-17, 2015 ... an FDA inspector came to a facility today, would ... , If the answer is "maybe" or "no" … ... Enterprises and FDAnews have a solution. , Take ...
(Date:4/27/2015)... April 27, 2015 A new type of ... May 9. Science on Tap at the Science Museum of ... brews, but adds science hops for a bold, new flavor. ... trucks and serves up the science behind these frothy beverages. ... a first-hand look at the ingredients that go into beer ...
Breaking Medicine News(10 mins):Health News:PracticeMatch to Host Physician Career Fair at Sheraton Colonial Boston North Hotel on May 6, 2015 2Health News:PracticeMatch to Host Physician Career Fair at Sheraton Colonial Boston North Hotel on May 6, 2015 3Health News:Hot States for Medical Careers: Healthcare Staffing Agency Aureus Medical Releases Online Search Results 2Health News:Foot and Ankle Specialists of the Mid-Atlantic, LLC Podiatrist Receives Maryland Podiatric Medical Association Outstanding Service Award 2Health News:FDAnews Announces: Medical Device Design Control: Implementing an Approach That Works, June 16-17, Chicago, IL 2Health News:FDAnews Announces: Medical Device Design Control: Implementing an Approach That Works, June 16-17, Chicago, IL 3Health News:FDAnews Announces: Medical Device Design Control: Implementing an Approach That Works, June 16-17, Chicago, IL 4Health News:Science on Tap at the Science Museum of Virginia 2
... KUNMING, China, Nov. 16 /PRNewswire-Asia-FirstCall/ -- ... Shenghuo" or,the "Company"), which is engaged in the research, ... products,in the People,s Republic of China ("PRC"), today reported ... 2009. , , Third Quarter 2009 ...
... resonance images (MRI) of patients diagnosed with multiple sclerosis ... more aggressive, and causes more brain lesions, than MS ... have reported. , Interestingly, however, patients with pediatric-onset MS ... MS cases -- develop disabilities at a slower pace ...
... to treatment for chlamydia, gonorrhea, syphilis is ,imperative, expert ... girls aged 15 to 19 accounted for the largest ... gonorrhea cases in the United States in 2008, followed ... annual federal report released Monday. , The researchers also ...
... ... to grant an ill child’s dream to go to Disneyland , ... (PRWEB) November 16, 2009 -- LeapFish has ... that dream come true. Tweet-a-Cause, a social media fundraising initative, will give Twitter users the ...
... 16 The nation,s premier public health agency, the Centers ... contract with Georgia Power to purchase renewable energy for its ... http://www.newscom.com/cgi-bin/prnh/20050216/CLW066LOGO ) , The purchase of more than ... organization,s annual kilowatt-hour consumption, will make the CDC Georgia Power,s ...
... A powerful new breast cancer treatment could result ... cancer,s hallmark wild growth with another that blocks a ... part of itself, researchers say. While they are ... called histone deacetylase inhibitors, or HDAC inhibitors, also increase ...
Cached Medicine News:Health News:China Shenghuo Reports Unaudited Financial Results for the Third Quarter of 2009 2Health News:China Shenghuo Reports Unaudited Financial Results for the Third Quarter of 2009 3Health News:China Shenghuo Reports Unaudited Financial Results for the Third Quarter of 2009 4Health News:China Shenghuo Reports Unaudited Financial Results for the Third Quarter of 2009 5Health News:China Shenghuo Reports Unaudited Financial Results for the Third Quarter of 2009 6Health News:China Shenghuo Reports Unaudited Financial Results for the Third Quarter of 2009 7Health News:China Shenghuo Reports Unaudited Financial Results for the Third Quarter of 2009 8Health News:China Shenghuo Reports Unaudited Financial Results for the Third Quarter of 2009 9Health News:China Shenghuo Reports Unaudited Financial Results for the Third Quarter of 2009 10Health News:China Shenghuo Reports Unaudited Financial Results for the Third Quarter of 2009 11Health News:MS is more aggressive in children but slower to cause disability than in adults 2Health News:MS is more aggressive in children but slower to cause disability than in adults 3Health News:Teen Girls at Higher Risk for STDs: Report 2Health News:LeapFish and Make-a-Wish Foundation Join Forces to Raise $10,000 and Tweet an Ill Child's Wish True 2Health News:Georgia Power, Centers for Disease Control and Prevention Forge Green Energy Partnership 2Health News:New combination therapy could deliver powerful punch to breast cancer 2
MultiWash Advantage is a versatile microplate washer engineered for reliability. It is designed for lab environments to help streamline their daily processes....
... for the determination of A1c is also designed ... Plus is a fully automated analyzer including primary ... ultimate in safety and positive identification. The analysis ... to be interference-free and to produce the lowest ...
... Maximize your laboratorys productivity ... enhanced automated workflow management. ... automated workstation now completely ... immunoassay with specimen processing ...
... The STart 4 semi-automated hemostasis analyzer ... electro-mechanical clot detection (Viscosity-based Detection System). ... icteric or other optically turbid samples ... offers programmable and preprogrammed assays with ...
Medicine Products: